Liraglutide has less adverse cardiovascular outcomes than placebo
Metadata[+] Show full item record
Bottom line: Liraglutide appears to lead to less death from CV causes, nonfatal MI, and stroke compared with placebo in patients with type 2 diabetes, but also has higher discontinuation rates. This trial did not achieve the criteria for a PURL because many practitioners are using GLP-1 agonists already.
Evidence-based practice 20, no. 7 (2017): 04